Marlène Hekman Tumor-targeted imaging of cancer with radiolabeled and fluorescently labeled antibodiesThe aim of the studies described in this thesis was the clinical translation of targeted imaging using radiolabeled and fluorescently labeled antibodies. By conjugating a radionuclide or a fluorescent molecule to an antibody, a tumor-targeting imaging tracer is created that can be used to visualize tumors. The preclinical studies have shown the additional value of dual-modality imaging in the detection of small tumors in models for colorectal and ovarian cancer. Next, two clinical applications of targeted imaging with girentuximab in clear cell renal cell carcinoma (ccRCC) were described; as a diagnostic tool for ccRCC (89Zr-girentuximab) and for intraoperative guidance of ccRCC resection (111In-girentuximab-IRDye800CW).This thesis shows that sensitive non-invasive or intraoperative imaging techniques can improve the management of patients with cancer. Ultimately, the combination of several intraoperative techniques may deliver the best information to lead patient management in a personalized fashion.
Date, time and location PhD defense
- Date: 7 December 2018
- Time: 10:30 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
Marlène Hekman (1988) obtained her medical degree with first-class honors in 2013 from Groningen university. She carried out the above doctoral research at the Departments of Urology and Radiology & Nuclear medicine of the Radboudumc within the Radboud Institute for Molecular Life Sciences. In July 2017 she entered the residency program in Urology and is currently working in the Canisius Wilhelmina Hospital in Nijmegen.
- Promotor(s): Prof. P.F.A. Mulders and Prof. O.C. Boerman
- Co-promotor(s): M.J.P. Rijipkema, PhD and E. Oosterwijk, PhD